HalioDx is an immuno-oncology diagnostic company providing oncologists with first-in-class Immune-based diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies.

HalioDx designs and develops in-vitro diagnostic products in the immuno-oncology field. The company offers a range of immune scoring tests. It offers ImmunoscoreCC, a decision making tool to clinicians for patients management based on anti-tumor immune response. 

HalioDx was founded in 2014 by Dr Jérôme Galon. The company is based in Paris, Ile-de-France, France with an additional office in Richmond, Virginia.

HalioDx Immunoscore® technology integrates immunohistochemistry combined with advanced imaging analysis enabling extraction of spatially-organized tissue molecular information.

HalioDx collaborates with an increasing number of renowned international clinical groups and biopharmaceutical companies to support clinical utility and ensure rigorous performance validation of its assays in a large number of cancer indications.

HalioDx executes biomarker studies and companion diagnostic assay development in conformity with regulations and in partnership with biopharmaceutical companies.

HalioDx's investors include Quest for Growth, BNP Paribas Développement, & PSIM fund among others.



  • Year founded: 2014
  • Funding Info: €26.5M in 2 funding rounds (Last Funding Type: Series B)
  • Yearly Revenue: $10M to $20M (2018)
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: Marseille
  • Country: France
Related businesses